STOCK TITAN

Eupraxia Pharmaceuticals (EPRX) schedules June 18, 2026 annual meeting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Eupraxia Pharmaceuticals Inc. has scheduled its Annual General Meeting of security holders for June 18, 2026. Holders of common shares on the record date of May 8, 2026 are entitled to receive notice of the meeting and to vote. The meeting is described as an Annual General Meeting, with common shares being the sole class eligible for notice and voting rights. Proxy-related and delivery details for beneficial owners are addressed through TSX Trust Company.

Positive

  • None.

Negative

  • None.
Meeting date June 18, 2026 Date fixed for the Annual General Meeting of security holders
Record date for notice May 8, 2026 Determines which holders receive notice of the meeting
Record date for voting May 8, 2026 Determines which holders may vote at the meeting
Beneficial ownership determination date May 8, 2026 Date for establishing beneficial ownership for the AGM
Annual General Meeting financial
"upcoming Annual General Meeting of Security Holders for the subject issuer"
Record Date for Voting financial
"Record Date for Voting: | | May 8, 2026"
Beneficial Ownership Determination Date financial
"Beneficial Ownership Determination Date: | | May 8, 2026"
Non-Objecting Beneficial Owners financial
"Reporting issuer is sending proxy-related materials directly to Non-Objecting Beneficial Owners"
Non-objecting beneficial owners are individual or institutional shareholders who hold stock through a broker or bank and have allowed that intermediary to share their name and contact details with the company that issued the shares. This matters to investors because it lets companies contact those shareholders directly about votes, proxy materials, tender offers or corporate updates, which can speed communication and influence participation much like a sender getting permission to mail you directly rather than through a forwarding service.

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number: 001-41923

Eupraxia Pharmaceuticals Inc.

(Translation of registrant’s name into English)

201-2067 Cadboro Bay Road

Victoria, British Columbia, Canada V8R 5G4

Telephone : (250) 590-3968

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☐ Form 40-F

 

 
 


DOCUMENTS INCLUDED AS PART OF THIS REPORT

 

Exhibit     
99.1    Notice of Record and Meeting Date


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

         

Eupraxia Pharmaceuticals Inc..

      (Registrant)

Date: April 14, 2026

     

/s/ Alex Rothwell

      Alex Rothwell
      Chief Financial Officer

Exhibit 99.1

 

LOGO

TSX TRUST COMPANY

VIA ELECTRONIC TRANSMISSION

April 13, 2026

TO ALL APPLICABLE EXCHANGES AND COMMISSIONS:

 

RE:

EUPRAXIA PHARMACEUTICALS INC.

Confirmation of Notice of Record and Meeting Dates

 

We are pleased to confirm that the Notice of Record and Meeting Dates was sent to The Canadian Depository for Securities.

We advise the following with respect to the upcoming Annual General Meeting of Security Holders for the subject issuer:

 

1    ISIN:    CA29842P1053
   CUSIP:    29842P105
2    Date Fixed for the Meeting:    June 18, 2026
3    Record Date for Notice:    May 8, 2026
4    Record Date for Voting:    May 8, 2026
5    Beneficial Ownership Determination Date:    May 8, 2026
6    Classes or Series of Securities that entitle the holder to receive Notice of the Meeting:    COMMON SHARES
7    Classes or Series of Securities that entitle the holder to vote at the meeting:    COMMON SHARES
8    Business to be conducted at the meeting:    Annual General
9    Notice-and-Access:   
  

Registered Shareholders:

   NO
  

Beneficial Holders:

   NO
   Stratification Level:    Not Applicable
10    Reporting issuer is sending proxy-related materials directly to Non-Objecting Beneficial Owners:    NO
11    Issuer paying for delivery to Objecting Beneficial Owners:    NO

Yours truly,

TSX Trust Company

 

VANCOUVER    CALGARY    TORONTO    MONTRÉAL
733 Seymour Street,    Telus Sky Building    301 - 100 Adelaide Street West    1701 - 1190, avenue des
Suite #2310    2110, 685 Centre Street SW    Toronto ON M5H 4H1    Canadiens-de-Montréal, C. P. 37
Vancouver, BC V6B 0S6    Calgary Alberta T2G 1S5       Montréal (Québec) H3B 0G7
      Toll Free 1-866-600-5869   
T 604 689-3334    T 403 218-2800    T 416 361-0930    T 514 395-5964

FAQ

When is Eupraxia Pharmaceuticals (EPRX) holding its 2026 annual meeting?

Eupraxia Pharmaceuticals will hold its Annual General Meeting of security holders on June 18, 2026. This meeting date is confirmed by TSX Trust Company and applies to all eligible common shareholders of the issuer as outlined in the notice of record and meeting dates.

What is the record date for Eupraxia Pharmaceuticals (EPRX) 2026 AGM?

The record date for notice and voting at Eupraxia Pharmaceuticals’ 2026 Annual General Meeting is May 8, 2026. Shareholders who hold common shares on that date are entitled to receive meeting materials and exercise their voting rights at the scheduled annual meeting.

Which Eupraxia (EPRX) securities can vote at the June 18, 2026 meeting?

Only common shares of Eupraxia Pharmaceuticals entitle holders to receive notice of, and vote at, the June 18, 2026 Annual General Meeting. No other classes or series are listed as eligible, so voting rights are confined to holders of the company’s common shares as of the record date.

What type of business will Eupraxia (EPRX) conduct at the 2026 meeting?

The company will conduct business described simply as “Annual General” at the June 18, 2026 meeting. This indicates a standard annual general meeting of security holders, as noted in the confirmation sent via TSX Trust Company to applicable exchanges and commissions.

What is the beneficial ownership determination date for Eupraxia (EPRX) 2026 AGM?

The beneficial ownership determination date for Eupraxia Pharmaceuticals’ 2026 Annual General Meeting is May 8, 2026. This date aligns with the record date for notice and voting, helping define which beneficial holders are recognized for receiving materials and participating in the meeting.

Filing Exhibits & Attachments

1 document